Research reportSeverity classification on the Hamilton depression rating scale
Introduction
The importance of severity in selecting and evaluating the efficacy of treatment for depressed patients has received increased attention recently. The Third Edition of the American Psychiatric Association's (APA's) guidelines for the treatment of major depressive disorder recommended both psychotherapy and pharmacotherapy as monotherapies for depression of mild and moderate severity, and pharmacotherapy (with or without psychotherapy) for severe depression (American Psychiatric Association, 2010). The National Institute for Health and Clinical Excellence (NICE) updated guidelines for the treatment and management of depression discouraged the use of antidepressant medication as the initial treatment option for mild depression, and recommended medication together with empirically supported psychotherapy for moderate and severe depression (National Collaborating Center for Mental Health, 2009). As reported by van der Lem et al. (2011), treatment guidelines in the Netherlands also recommended pharmacotherapy as the first treatment option for severely depressed patients, and either pharmacotherapy or psychotherapy for mildly and moderately depressed patients. While the recommendations in these guidelines are not entirely consistent, they are unanimous in recommending medication as the treatment of choice for severe depression.
Symptom severity as a moderator of treatment response has been the subject of ongoing debate since the publication of the results from the National Institute of Mental Health Treatment of Depression Collaborative Research Program (TDCRP) suggesting that psychotherapy was not as effective as medication in the acute treatment of severe depression (Elkin et al., 1995, Elkin et al., 1989). In 1999, DeRubeis et al. (1999) noted that treatment guidelines from the American Psychiatric Association (1993) and Agency for Health Care Policy and Research (1993) recommended antidepressant medication, and not psychotherapy, for severe depression, and these recommendations were largely based on the findings of the TDCRP. The importance of severity was recently renewed in another context—the range of effectiveness of antidepressant medication. Kirsch et al. (2008) conducted a meta-analysis of antidepressant treatment trials in the FDA data base and found that drug-placebo differences increased as baseline severity increased, and concluded that antidepressants were only minimally more effective than placebo for mildly and moderately depressed patients. This conclusion was reinforced by the results of a mega-analysis of 6 studies by Fournier et al. (2010), though a recent, larger, mega-analysis found that the efficacy of two antidepressants, fluoxetine and venlafaxine, over placebo was independent of severity (Gibbons et al., 2012). The severity of depression has also continued to retain importance in moderating the effect of psychotherapy, though a recent meta-analysis of psychotherapy studies found that greater symptom severity did not predict poorer response in controlled studies examining the moderating effect of severity (Driessen et al., 2010).
Each of these meta- and mega-analyses used the Hamilton Depression Rating Scale (HAMD) (1960), wholly, or in part, to define severity, though the cutoff used to define severe depression varied. DeRubeis et al. (1999) conducted a mega-analysis of 4 studies comparing cognitive-behavioral therapy and medication. Following the precedent of the TDRCP, DeRubeis et al. defined severe depression as a cutoff of 20 or more on the 17-item HAMD. Likewise, the recent mega-analysis of placebo-controlled trials of fluoxetine and venlafaxine cited the TDRCP in using a cutoff >20 to define severe depression. Of note, no empirical justification was given in the TDRCP for using this threshold to define severe depression (Elkin et al., 1989). In fact, Elkin et al.'s (1989) did not refer to the patients scoring above 20 on the HAMD in absolute terms (i.e., having severe depression), but instead referred to them in relative terms (i.e., having more severe depression than the patients scoring 20 and below). In Kirsch et al. (2008) meta-analysis the authors noted that the mean baseline HAMD scores of the antidepressant efficacy trials were in the very severe range (i.e., ≥23 based on the APA's Handbook of Psychiatric Measures (Rush et al., 2008) for all but 2 of the 35 studies included in the analysis. Prior to the report by Kirsch and colleagues, Khan et al. (2002) examined the FDA data base, and also found that drug-placebo differences increased with increasing mean baseline HAMD scores. Khan et al. (2002) divided the studies into 3 groups based on pretreatment HAMD scores (≤24, 25–27, ≥28) without indicating the basis for using these cutoff scores to define the groups. Fournier et al. (2010) used the thresholds recommended in the APA's Handbook of Psychiatric Measures (Rush et al., 2008) to define grades of severity on the HAMD (mild to moderate≤18; severe 19 to 22; very severe ≥23).
In contrast to all of these studies, and the APA guidelines, most pharmacotherapy studies have used a cutoff of 25 on the 17-item HAMD to define severe depression (Dunner et al., 2005, Kasper, 1997, Montgomery et al., 2003, Schmitt et al., 2009, Shelton et al., 2007, Versiani et al., 2005), and this cutoff has been recommended by several experts to define severe depression (Hirschfeld, 1999, Montgomery and Lecrubier, 1999, Schatzberg, 1999).
Fundamental to all of these studies on the treatment implications of severity is the validity of the cutoffs on the HAMD to define the severity categories. In none of the discussion sections of these reports were questions raised about the cutoffs used to define the grades of severity. The APA's Handbook of Psychiatric Rating Scales (Rush et al., 2008) cited two studies in support of the cutoff scores to identify severity subtypes. One was a study examining the validity of deriving a HAMD equivalent score on the Schedule for Affective Disorders and Schizophrenia (Endicott et al., 1981). In fact, this study did not attempt to determine the cutoff scores on the HAMD indicating grades of severity. Rather, when examining the agreement between the extracted and original HAMD in classifying patients into severity categories, the authors used a cutoff of 25 to indicate severe depression (and a cutoff of 18 to distinguish mild and moderate depression). The second study cited as evidence for using a cutoff of 23 to indicate severe depression examined the association between HAMD scores and global ratings of severity in 59 depressed inpatients (Kearns et al., 1982). The authors did not derive (or recommend) cutoff scores corresponding to severity levels. In Figure 2 of their paper, the authors graphed the mean HAMD for patients rated at different levels of severity. Visual inspection of this figure suggests that very severe depression corresponded to a mean HAMD score of approximately 29 and severe depression corresponded to a mean HAMD score of 21. If these groups were combined, the mean HAMD for the severe category would be approximately 25. Thus, it is unclear why a cutoff of 19 was recommended in the APA Handbook to identify severe depression. We are aware of only 2 other small studies comparing HAMD scores to clinical global severity ratings. Knesevich et al. (1977) evaluated a sample of 26 outpatients, 9 of whom were rated in the severe range. Visual inspection of the figure plotting the distribution of scores suggests that the median score for these patients was 24. Muller et al. (2003) evaluated 85 depressed inpatients, 26 of whom were rated severe. The results of a receiver operating curve analysis to determine the optimal cutoff score on the HAMD to indicate severe depression found that a cutoff of 25 provided the best balance of sensitivity and specificity.
There is thus a limited amount empirical research establishing cutoff scores for bands of severity on the HAMD. Because of the significance accorded severity by treatment guidelines it is important to empirically establish cutoff scores on the HAMD in the allocation of patients to severity groups. Accordingly, in the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project we compared HAMD scores to clinician global ratings of severity in a large sample of depressed outpatients.
Section snippets
Methods
The Rhode Island MIDAS project represents an integration of research methodology into a community-based outpatient practice affiliated with an academic medical center (Zimmerman, 2003). A comprehensive diagnostic evaluation is conducted upon presentation for treatment. This private practice group predominantly treats individuals with medical insurance (including Medicare but not Medicaid) on a fee-for-service basis, and it is distinct from the hospital's outpatient residency training clinic
Results
The mean score on the CGI was 3.1 (SD=.5) corresponding to a moderate level of severity. A small number of patients were rated extremely depressed (.8%, n=5), and these patients were included in the severe group. The majority of the patients were rated as having moderate depression (73.5%, n=461). More patients were rated as having severe depression (18.5%, n=116) than mild depression (7.5%, n=47). Two patients were rated as having minimal depression during the week prior to the evaluation and
Discussion
Treatment guidelines for depression suggest that it is important to consider severity when selecting a patient's initial treatment modality (American Psychiatric Association, 2010, et al.,, van der Lem et al., 2011). That is, for severely depressed patients the guidelines indicate that pharmacotherapy is the treatment of choice, whereas for mildly and moderately depressed patients both pharmacotherapy and psychotherapy are recommended options. While the moderating effect of severity on the
Role of funding source
None.
Conflict of interest
None.
Acknowledgments
None.
References (39)
- et al.
Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials
Clinical Therapeutics
(2005) - et al.
Is severe depression a separate indication?
European Neuropsychopharmacology
(1999) - et al.
Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS)
Journal of Affective Disorders
(2003) - et al.
Response and remission criteria in major depression—a validation of current practice
Journal of Psychiatric Research
(2010) - et al.
Heterogeneity among depressed outpatients considered to be in remission
Comprehensive Psychiatry
(2007) - Agency for Health Care Policy and Research, 1993. Clinical practice guideline: depression in primary care, treatment of...
Practice Guideline for Major Depressive Disorder in Adults
American Psychiatric Association, Washington, DC
(1993)Practice Guideline for the Treatment of Patients With Major Depressive Disorder
(2010)- et al.
Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons
American Journal of Psychiatry
(1999) - et al.
Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis
Journal of Consulting and Clinical Psychology
(2010)
Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program
Journal of Consulting and Clinical Psychology
NIMH treatment of depression collaborataive research program: general effectiveness of treatments
Archives of General Psychiatry
Hamilton depression rating scale
Archives of General Psychiatry
A diagnostic interview: the schedule for affective disorders and schizophrenia
Archives of General Psychiatry
Structured Clinical Interview for DSM-IV Axis I Disorders—Patient edition (SCID-I/P, version 2.0).
Antidepressant drug effects and depression severity: a patient-level meta-analysis
Journal of the American Medical Association
Conceptualization and rationale for consensus definitions of terms in major depressive disorder
Archives of General Psychiatry
Benefits From antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine
Archives of General Psychiatry
ECDEU Assessment Manual for Psychopharmacology
Cited by (746)
Acculturation and clinical symptoms of schizophrenia among Latine adults in the United States
2024, Schizophrenia ResearchVentral targeted anterior capsulotomy for treatment-resistant depression and obsessive-compulsive disorder: A treatment method with cases
2024, Journal of Affective DisordersRapid response to antidepressants and correlation with response and remission after acute treatment
2024, Journal of Affective Disorders ReportsEfficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial
2024, Journal of Ayurveda and Integrative Medicine